已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor–Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study

医学 奥西默替尼 放射治疗 肺癌 临床终点 腺癌 表皮生长因子受体 临床研究阶段 内科学 新辅助治疗 肿瘤科 外科 化疗 癌症 埃罗替尼 临床试验 乳腺癌
作者
Nir Peled,Laila C. Roisman,Esther Levison,Julia Dudnik,Elena Chernomordikov,Norman Heching,Elizabeth Dudnik,Shoshana Keren-Rosenberg,Hovav Nechushtan,Ayman Salhab,Dov Hershkovitz,Shlomo Tsuriel,Victoria Hannes,Ofer Rotem,Irina Lazarev,Rachel Lichtenberg,Inbal S. Granot,Bilal Krayim,Walid Shalata,Daniel Levin,Yanay Krutman,Aaron M. Allen,Philip Blumenfeld,Konstantin Lavrenkov,Waleed Kian
出处
期刊:International Journal of Radiation Oncology Biology Physics [Elsevier]
卷期号:117 (1): 105-114 被引量:11
标识
DOI:10.1016/j.ijrobp.2023.03.042
摘要

The treatment for unresectable, locally advanced stage III non-small cell lung cancer (NSCLC) is concurrent chemoradiation therapy (CRT) followed by consolidation durvalumab. This study aimed to evaluate the benefit of neoadjuvant osimertinib as an alternative therapy to this approach with the aim of reducing the radiation field.This investigation was a nonrandomized, open-label, single-arm, phase 2, prospective, proof-of-concept study. Eligible patients were classified as having treatment-naïve, nonoperable, stage III epidermal growth factor receptor-mutant NSCLC. Patients received 80 mg of oral osimertinib daily for 12 weeks before definitive radiation therapy (RT) and/or surgery. The response was assessed at weeks 6 and 12. For responders, sequential definitive RT and/or surgery were planned. Nonresponders were started on standard CRT. After RT ± surgery or CRT, patients were followed for 2 years without adjuvant therapy. The primary endpoint was the objective response rate (ORR), with September 20, 2022, set as the cut-off for data collection. Secondary endpoints were safety and the gross tumor volume (GTV), planned tumor volume (PTV), and the percentage of total lung volume minus GTV exceeding 20 Gy (V20%) before versus after osimertinib. Exploratory analyses included assessments of the presence of plasma circulating tumor-free DNA (ctDNA) before osimertinib treatment, at weeks 6 and 12, at the end of RT, and 6 weeks post-RT.Twenty-four patients were included (19 women; median age, 73 years; range, 51-82 years). Nineteen of 24 had never smoked, 20 of 24 had adenocarcinoma, 16 of 24 had exon 19 deletions, and 8 of 24 had exon 21 mutations. Participants had stage IIIA (10), IIIB (9), or IIIC (5) disease. Three patients were excluded from the analysis (1 dropped out and 2 were still undergoing osimertinib treatment at the cut-off date). The ORR to induction osimertinib was 95.2% (17 partial response, 3 complete response, and 1 progressive disease). After induction osimertinib, 13 of 20 patients were definitively radiated, 3 of 20 underwent surgery, and 5 of 20 were excluded. Four patients were restaged as stage IV (contralateral ground-glass opacities responded to osimertinib), and 1 patient withdrew informed consent. Three patients underwent surgery, one of whom was treated with RT. Two patients achieved pT1aN0, and one achieved pathologic complete response. The median GTV, PTV, and V20% before osimertinib treatment were 47.4 ± 76.9 cm3 (13.5-234.9), 227.0 ± 258.8 cm3 (77.8-929.2), and 27.1 ± 16.4% (6.2-60.3), respectively. The values after osimertinib treatment were 27.5 ± 42.3 cm3 (2.99-137.7; -48 ± 20%; P = .02), 181.9 ±198.4 cm3 (54-718.1; -31 ± 20%; P = .01), and 21.8 ± 11.7% (9.1-44.15; -24 ± 40%; P = .04), respectively. PTV/GTV/V20% reduction was associated with tumor size and central location. The median follow-up time was 28.71 months (range, 0.4-45.1 months), and median disease-free survival was not reached (mean, 30.59; standard error, 3.94; 95% confidence interval, 22.86-38.31). ctDNA was detected in 5 patients; 4 of 5 were positive for ctDNA at baseline and became negative during osimertinib induction but were again positive after osimertinib treatment was terminated. Interestingly, 3 patients who were ctDNA negative at baseline became weakly positive after RT and then were negative at follow-up. No significant adverse events were reported during the osimertinib or radiation phases.Neoadjuvant osimertinib therapy is feasible in patients with stage III lung cancer NSCLC, followed by definitive radiation and/or surgery, with an ORR of 95.2% and an excellent safety profile. Osimertinib induction for 12 weeks before definitive radiation (chemo-free) significantly reduced the radiation field by nearly 50% with a linear association with tumor size. Further studies are needed to test this chemo-free approach for long-term outcomes before practices are changed.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
么系么系发布了新的文献求助10
1秒前
kokocrl完成签到,获得积分10
4秒前
5秒前
Lyanph完成签到 ,获得积分10
5秒前
干净水彤完成签到 ,获得积分10
5秒前
8秒前
科研通AI2S应助科研通管家采纳,获得10
9秒前
wanci应助科研通管家采纳,获得10
9秒前
李爱国应助科研通管家采纳,获得10
9秒前
orixero应助科研通管家采纳,获得10
9秒前
充电宝应助科研通管家采纳,获得10
9秒前
9秒前
9秒前
10秒前
lu完成签到,获得积分10
10秒前
科研通AI2S应助kk采纳,获得30
11秒前
IrisYu发布了新的文献求助10
11秒前
上文卜完成签到,获得积分10
12秒前
Aric发布了新的文献求助10
13秒前
红红发布了新的文献求助10
14秒前
cc发布了新的文献求助10
18秒前
么系么系完成签到,获得积分10
19秒前
左眼天堂发布了新的文献求助20
19秒前
20秒前
21秒前
轻松万天发布了新的文献求助10
24秒前
神奇小鹿完成签到 ,获得积分10
24秒前
泥巴发布了新的文献求助10
25秒前
26秒前
Tiwiiw完成签到 ,获得积分10
27秒前
小杏韵发布了新的文献求助10
28秒前
28秒前
34秒前
35秒前
嘻嘻完成签到,获得积分10
37秒前
学渣本渣发布了新的文献求助10
41秒前
43秒前
Owen应助无辜的代梅采纳,获得10
45秒前
Xu完成签到 ,获得积分10
48秒前
结实的荷发布了新的文献求助10
50秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Very-high-order BVD Schemes Using β-variable THINC Method 830
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3248551
求助须知:如何正确求助?哪些是违规求助? 2891977
关于积分的说明 8269308
捐赠科研通 2560053
什么是DOI,文献DOI怎么找? 1388842
科研通“疑难数据库(出版商)”最低求助积分说明 650913
邀请新用户注册赠送积分活动 627798